Recombinant factor VII is associated with worse survival in complex cardiac surgical patients

Annals of Thoracic Surgery

Volumn 98, Issue 2, 2014, Pages 618-624

  Alfirevic, Andrej ^a   Duncan, Andra ^a   You, Jing ^a   Lober, Cheryl ^a   Soltesz, Edward ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ADVERSE OUTCOME; AGED; AORTA SURGERY; ARTICLE; BLOOD TRANSFUSION; CARDIAC PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFECT; END STAGE RENAL DISEASE; FEMALE; HEART FAILURE; HEART INFARCTION; HEART SURGERY; HEART VALVE REPLACEMENT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; SURGICAL PATIENT; SURVIVAL; THORAX SURGERY; THROMBOEMBOLISM;

CARDIAC SURGICAL PROCEDURES; FACTOR VIIA; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84905592238     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2014.04.126     Document Type: Article

References (34)

1. K. Karkouti, D.N. Wijeysundera, and T.M. Yau et al. The independent association of massive blood loss with mortality in cardiac surgery Transfusion 44 2004 1453 1462
2. A. Vivacqua, C.G. Koch, and A.M. Yousuf et al. Morbidity of bleeding after cardiac surgery: is it blood transfusion, reoperation for bleeding, or both? Ann Thorac Surg 91 2011 1780 1790
3. B.A. Whitson, S.J. Huddleston, K. Savik, and S.J. Shumway Bloodless cardiac surgery is associated with decreased morbidity and mortality J Card Surg 22 2007 373 378
4. S.A. Mayer, N.C. Brun, K. Begtrup FAST Trial Investigators Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage N Engl J Med 358 2008 2127 2137
5. C.J. Hauser, K. Boffard, R. Dutton CONTROL Study Group Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage J Trauma 69 2010 489 500
6. M. Hacquard, M. Durand, T. Lecompte, S. Boini, S. Briançon, and J.P. Carteaux Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7) Eur J Cardiothorac Surg 40 2011 1320 1327
7. C. Willis, R. Bird, D. Mullany, P. Cameron, and L. Phillips Use of rFVIIa for critical bleeding in cardiac surgery: dose variation and patient outcomes Vox Sang 98 2010 531 537
8. P. Diprose, M.J. Herbertson, D. O'Shaughnessy, C.D. Deakin, and R.S. Gill Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage Br J Anaesth 94 2005 271 278
9. R. Gill, M. Herbertson, and A. Vuylsteke et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery Circulation 120 2009 21 27
10. K. Karkouti, W.S. Beattie, and D.N. Wijeysundera et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis Transfusion 45 2005 26 34
11. K. Karkouti, W.S. Beattie, and R. Arellano et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery Circulation 118 2008 331 338
12. N.D. Andersen, S.D. Bhattacharya, and J.B. Williams et al. Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations Ann Thorac Surg 93 2012 1921 1929
13. M. Ranucci, G. Isgrò, G. Soro, D. Conti, and B. De Toffol Efficacy and safety of recombinant activated factor VII in major surgical procedures: systematic review and meta-analysis of randomized clinical trials Arch Surg 143 2008 296 304
14. A.J. Chapman, A.L. Blount, A.T. Davis, and R.L. Hooker Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery Eur J Cardiothorac Surg 40 2011 1314 1319
15. A. Villar, S. Aronis, and M. Morfini et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A Haemophilia 10 2004 352 359
16. B.A. Bruckner, D.J. DiBardino, and Q. Ning et al. High incidence of thromboembolic events in left ventricular assist device patients treated with recombinant activated factor VII J Heart Lung Transplant 28 2009 785 790
17. M. Levi, J.H. Levy, H.F. Andersen, and D. Truloff Safety of recombinant activated factor VII in randomized clinical trials N Engl J Med 363 2010 1791 1800
18. T. Abshire, and G. Kenet Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors Haemophilia 14 2008 898 902
19. B. Mitra, L. Phillips, P.A. Cameron, B. Billah, and C. Reid The safety of recombinant factor VIIa in cardiac surgery Anaesth Intensive Care 38 2010 671 677
20. M. Ponschab, G. Landoni, and G. Biondi-Zoccai et al. Recombinant activated factor VII increases stroke in cardiac surgery: a meta-analysis J Cardiothorac Vasc Anesth 25 2011 804 810
21. S. Gelsomino, R. Lorusso, and S. Romagnoli et al. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis Eur J Cardiothorac Surg 33 2008 64 71
22. K.A. O'Connell, J.J. Wood, R.P. Wise, J.N. Lozier, and M.M. Braun Thromboembolic adverse events after use of recombinant human coagulation factor VIIa JAMA 295 2006 293 298
23. T.L. Higgins, F.G. Estafanous, F.D. Loop, G.J. Beck, J.M. Blum, and L. Paranandi Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score JAMA 267 1992 2344 2348
24. S.B. Bull Regression models for multiple outcomes in large epidemiologic studies Stat Med 17 1998 2179 2197
25. Z.H. Endre Acute kidney injury: definitions and new paradigms Adv Chronic Kidney Dis 15 2008 213 221
26. A. Kuitunen, A. Vento, R. Suojaranta-Ylinen, and V. Pettilä Acute renal failure after cardiac surgery: evaluation of the RIFLE classification Ann Thorac Surg 81 2006 542 546
27. B.G. Loef, A.H. Epema, and T.D. Smilde et al. Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival J Am Soc Nephrol 16 2005 195 200
28. A.E. Pusateri, and M.S. Park Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma Crit Care 9 Suppl 5 2005 S15 S24
29. W. Dietrich, and M. Spannagl Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery Anesth Analg 94 2002 1369 1370 author reply 1370-1
30. M. Ernofsson, S. Thelin, and A. Siegbahn Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study J Thorac Cardiovasc Surg 113 1997 576 584
31. T.A. Drake, J.H. Morrissey, and T.S. Edgington Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis Am J Pathol 134 1989 1087 1097
32. G. Kenet High-dose recombinant factor VIIa therapy in hemophilia patients with inhibitors Semin Hematol 43 1 Suppl 1 2006 S108 S110
33. E.M. van de Garde, L.J. Bras, and R.H. Heijmen et al. Low-dose recombinant factor VIIa in the management of uncontrolled postoperative hemorrhage in cardiac surgery patients J Cardiothorac Vasc Anesth 20 2006 573 575
34. C.D. Willis, P.A. Cameron, and L. Phillips Variation in the use of recombinant activated factor VII in critical bleeding Intern Med J 40 2010 486 493